The biomarker-based ABC-stroke score outperformed CHA2DS2-VASc and ATRIA, achieving C indices of 0.65 compared to 0.60 and 0.61, respectively (P < 0.05).
Does the biomarker-based ABC-stroke score improve stroke risk prediction compared to CHA2DS2VASc and ATRIA scores in anticoagulated patients with atrial fibrillation?
8,356 anticoagulated patients with atrial fibrillation from the RE-LY trial, median age 72, 36.7% female, multinational (44 countries). Key inclusion: documented AF and at least one risk factor for stroke (previous stroke/TIA, CHF or LVEF <40%, age >=75, or age >=65 with diabetes mellitus, hypertension, or coronary artery disease). Key exclusion: severe heart valve disorder, recent stroke, creatinine clearance <30 mL/min, or active liver disease.
ABC-stroke risk score (incorporating age, biomarkers [N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac troponin T or I], and clinical history of prior stroke/transient ischemic attack)
CHA2DS2VASc and ATRIA clinical risk scores
Adjudicated stroke (ischemic, hemorrhagic, or unspecified) or systemic embolic eventshard clinical
The biomarker-based ABC-stroke score provides superior stroke risk prediction compared to standard clinical scores (CHA2DS2VASc and ATRIA) in anticoagulated patients with atrial fibrillation.
Background: Atrial fibrillation is associated with increased but variable risk of stroke. Our aim was to validate the recently developed biomarker-based ABC (age, biomarkers high-sensitivity troponin and N-terminal fragment B-type natriuretic peptide, and clinical history of prior stroke/transient ischemic attack)-stroke risk score and compare its performance with the CHA 2 DS 2 VASc and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) risk scores. Methods: The ABC-stroke score includes age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac troponin), and clinical history (prior stroke). This validation was based on 8356 patients, 16 137 person-years of follow-up, and 219 adjudicated stroke or systemic embolic events in anticoagulated patients with atrial fibrillation in the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy). Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardiac troponin I (hs-cTnI) were determined in plasma samples obtained at study entry. Results: The ABC-stroke score was well calibrated with 0.76 stroke/systemic embolic events per 100 person-years in the predefined low (2%/y) risk group for the ABC-stroke score with hs-cTnT. Hazard ratios for stroke/systemic embolic events were 1.95 for medium- versus low-risk groups, and 3.44 for high- versus low-risk groups. ABC-stroke score achieved C indices of 0.65 with both hs-cTnT and hs-cTnI, in comparison with 0.60 for CHA 2 DS 2 VASc ( P =0.004 for hs-cTnT and P =0.022 hs-cTnI) and 0.61 for ATRIA scores ( P =0.005 hs-cTnT and P =0.034 for hs-cTnI). Conclusions: The biomarker-based ABC-stroke score was well calibrated and consistently performed better than both the CHA 2 DS 2 VASc and ATRIA stroke scores. The ABC score should be considered an improved decision support tool in the care of patients with atrial fibrillation. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifiers: ARISTOTLE, NCT00412984; RE-LY, NCT00262600.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jonas Oldgren
Ziad Hijazi
Johan Lindbäck
Circulation
Boston University
Uppsala University
University Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Oldgren et al. (Mon,) reported a other. The biomarker-based ABC-stroke score outperformed CHA2DS2-VASc and ATRIA, achieving C indices of 0.65 compared to 0.60 and 0.61, respectively (P < 0.05).
www.synapsesocial.com/papers/698e30bae3d33b50e18365c3 — DOI: https://doi.org/10.1161/circulationaha.116.022802